NEW YORK (GenomeWeb) – Emerging biotechnology company Locus Biosciences announced today that it has closed a $5 million convertible note, and will use the funds to support the development of antimicrobial therapeutics based on CRISPR-Cas3 technology.

Financing for the round was led by Chinese Internet services provider Tencent Holdings and was joined by the North Carolina Biotechnology Center. Locus said the funding will help it advance development on several infectious disease products targeting antibiotic resistant infections and other microbiome-related diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.